Key result
18F-florbetaben PET detects cardiac amyloidosis, particularly AL forms, and identifies extracardiac AL infiltrates.
Why the study?
F-florbetaben PET is reported to detect cardiac amyloidosis, particularly AL forms, and sites of extracardiac AL-amyloid infiltrates, but its diagnostic performance and differentiation between AL-CA and ATTR-CA needed evaluation.
Does 18F-florbetaben PET imaging identify cardiac amyloidosis and differentiate AL-CA from ATTR-CA?
Population
61 patients with cardiac amyloidosis (AL and ATTR) and controls
Comparison
AL-CA vs ATTR-CA and controls using 18F-florbetaben PET whole-body imaging
Design
Cross-sectional study
Authors
Loading...
May enable comprehensive non-invasive AL staging in practice; extends cardiac PET imaging to extracardiac sites.
Cross-Sectional (n=61)
Does 18F-florbetaben PET imaging identify cardiac amyloidosis and differentiate AL-CA from ATTR-CA?
Effect estimate: kappa 0.871
p-value: p=< 0.001
18F-florbetaben PET imaging can effectively identify cardiac amyloidosis and differentiate between AL and ATTR subtypes, with diagnostic accuracy improved by combining cardiac and extracardiac uptake variables.
Sprauel et al. (2026) conducted a cross-sectional in Cardiac amyloidosis (AL and ATTR) (n=61). 18F-florbetaben PET vs. Controls and bone scan Perugini score was evaluated on Correct identification and differentiation of AL-CA from ATTR-CA using combined cardiac and extracardiac PET variables (kappa 0.871, p=< 0.001). 18F-florbetaben PET correctly identified 93% (57/61) of patients and differentiated AL from ATTR cardiac amyloidosis using combined cardiac and extracardiac variables.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: